GlyTherix Ltd is an Australian immuno-oncology company specializing in therapeutics for solid tumors, expressing Glypican-1 (GPC-1). GPC-1 occurs in many solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal, lung and ovarian cancers. It is not detectable in healthy tissue.

The company has a strong intellectual property position covering both its anti-GPC-1 antibody and the antigen itself, GPC-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope. GlyTherix has now completed a ‘First-in-Human’ trial of 12 patients using Miltuximab^® with no drug-related adverse events observed. GlyTherix is interested in partnerships or collaborations with larger pharmaceutical partners.

GlyTherix has:

– The ability to address a clear market need for new therapies to target solid tumors
– A clear development pathway
– A clear understanding of the requirements for the pipeline development programs
– The leadership team needed to manage the planned research programs
– A clear end goal which is to maximize the return on its intellectual property assets

Our anti-GPC-1 antibody is a first in class product. No-one else presently has an anti-GPC-1 therapy in clinical development for these cancers.

GlyTherix is raising capital to fund the commercialization of its anti-GPC-1 therapies. To download the current GlyTherix slide deck, click here.

Headquarters in Australia

We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Our reach is global, through partnerships with universities, research institutes, and companies.